Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2023 Jun;20(6):687-688.
doi: 10.1038/s41423-023-01010-3.

Author Correction: Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment

Xue Yang #  1   2   3   4 , Qing Li #  5 , Wenting Liu #  1   2 , Chen Zong  1   2 , Lixin Wei  1   2 , Yufang Shi  6   7 , Zhipeng Han  8   9
Affiliations
Published Erratum

Author Correction: Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment

Xue Yang et al. Cell Mol Immunol. 2023 Jun.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The role of MSCs in hepatic fibrosis formation and therapy. A, In the process of chronic inflammatory injury of liver, the synergistic effect from inflammation and the death of hepatocytes promotes the formation of hepatic fibrosis; B, The mechanisms of MSC therapy in hepatic fibrosis, including hepatic differentiation, hepatocyte protection, inhibition of HSC activation, ECM degradation and inflammation inhibition
Fig. 2
Fig. 2
Clinical trials of MSCs in liver diseases. A, An overall of clinical trials based on MSCs classified by liver disease type. B, Clinical trials of liver cirrhosis based on MSCs classified by the clinical phase. C, Clinical trials of liver cirrhosis based on MSCs classified by status. The data showed the number and percentage
Fig. 3
Fig. 3
The parameters need to be standardized precisely in clinical application of MSCs in liver cirrhosis. Currently, MSCs used in clinical trials for liver cirrhosis treatment are obtained from different sources (bone marrow, umbilical cord, adipose tissue, and menstrual blood). During the process of MSC preparation, there are various imprecise parameters, including donor seleciton, isolation methods, culture conditions, cryopreservation and thaw, and cell heterogeneity. MSCs are transferred at different dosages and through different routes. All of the above parameters would affect the therapeutic effect of MSCs and developing the best standard for clinical application of MSCs is essential for the successful clinical translation of MSCs in the future
Fig. 4
Fig. 4
Clinical trials of liver cirrhosis based on MSCs application. A, Clinical trials of liver cirrhosis based on different sources of MSCs. B, Clinical trials of liver cirrhosis based on autologous and allogeneic transplantation of MSCs. C, Clinical trials of liver cirrhosis based on transplantation routes of MSCs. The data showed the number and percentage of corresponding clinical trials
See this image and copyright information in PMC

Erratum for

Publication types